Evidera
Laura Shulak has a diverse work experience. Laura started their career at McGill University as a Graduate Teaching Assistant from August 2012 to May 2013. Laura then moved on to IC Axon, where they held various positions such as Medical Writer, Senior Medical Writer, Principal Medical Writer, and Medical Editor from March 2014 to March 2019. Most recently, they have been working at Evidera, where they started as a Lead Market Access Writer from April 2019 to October 2020, and then transitioned to the role of Associate Director, Market Access Communications from October 2020 to the present.
Laura Shulak completed their Master's Degree in Experimental Medicine from McGill University in 2014. The information provided does not include any details regarding their education before this period.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.